DK0705831T3 - Cycloalkano-indol- og -azaindol-derivater - Google Patents

Cycloalkano-indol- og -azaindol-derivater

Info

Publication number
DK0705831T3
DK0705831T3 DK95114877T DK95114877T DK0705831T3 DK 0705831 T3 DK0705831 T3 DK 0705831T3 DK 95114877 T DK95114877 T DK 95114877T DK 95114877 T DK95114877 T DK 95114877T DK 0705831 T3 DK0705831 T3 DK 0705831T3
Authority
DK
Denmark
Prior art keywords
opt
substd
alkyl
phenyl
alkoxy
Prior art date
Application number
DK95114877T
Other languages
English (en)
Inventor
Siegfried Dr Goldmann
Stefan Dr Wohlfeil
Hilmar Dr Bischoff
Ulrich Dr Mueller
Dirk Dr Denzer
Richard Dr Connell
Rudi Dr Gruetzmann
Martin Dr Beuck
Anke Dr Domdey-Bette
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of DK0705831T3 publication Critical patent/DK0705831T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK95114877T 1994-10-04 1995-09-21 Cycloalkano-indol- og -azaindol-derivater DK0705831T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4435477A DE4435477A1 (de) 1994-10-04 1994-10-04 Cycloalkano-indol- und -azaindol-derivate

Publications (1)

Publication Number Publication Date
DK0705831T3 true DK0705831T3 (da) 2004-04-05

Family

ID=6529939

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95114877T DK0705831T3 (da) 1994-10-04 1995-09-21 Cycloalkano-indol- og -azaindol-derivater

Country Status (36)

Country Link
US (6) US5684014A (da)
EP (1) EP0705831B1 (da)
JP (1) JP3901234B2 (da)
KR (1) KR100355986B1 (da)
CN (2) CN1050605C (da)
AT (1) ATE255580T1 (da)
AU (1) AU700609B2 (da)
CA (1) CA2159546C (da)
CZ (1) CZ291348B6 (da)
DE (2) DE4435477A1 (da)
DK (1) DK0705831T3 (da)
DZ (1) DZ1934A1 (da)
EE (1) EE03527B1 (da)
ES (1) ES2211890T3 (da)
FI (2) FI113048B (da)
HK (1) HK1005139A1 (da)
HN (1) HN1995009160A (da)
HR (1) HRP950505B1 (da)
HU (1) HU225052B1 (da)
IL (3) IL115493A (da)
MA (1) MA23683A1 (da)
MY (1) MY117282A (da)
NO (1) NO305365B1 (da)
NZ (1) NZ280130A (da)
PH (1) PH31400A (da)
PL (1) PL183154B1 (da)
PT (1) PT705831E (da)
RU (1) RU2157803C2 (da)
SG (1) SG63528A1 (da)
SI (1) SI0705831T1 (da)
SK (1) SK284260B6 (da)
SV (1) SV1995000062A (da)
TN (1) TNSN95098A1 (da)
TW (1) TW448175B (da)
UA (1) UA44700C2 (da)
ZA (1) ZA958297B (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19525028A1 (de) * 1995-07-10 1997-01-16 Bayer Ag Amide und Sulfonamide von heterocyclisch substituierten Benzylaminen
DE19613549A1 (de) * 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
US6774236B1 (en) 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
DE19615119A1 (de) 1996-04-17 1997-10-23 Bayer Ag Neue Arylessigsäureamide
DE19619950A1 (de) 1996-04-17 1997-10-23 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide
EP0802192A1 (de) * 1996-04-17 1997-10-22 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
NZ507391A (en) * 1998-05-01 2003-12-19 Lilly Co Eli The compound ((3-(2-amino-1,2-dioxoethyl)-2-methyl-1- (phenylmethyl)-1H-indol-4-yl)oxy)acetic acid N-morpholino ethyl ester and its use as a sPLA 2 inhibitor
ES2213984T3 (es) 1998-10-30 2004-09-01 Eli Lilly And Company Derivados de azaindol y su uso como agentes antitrombicos.
AU4616200A (en) * 1999-05-25 2000-12-12 Yamanouchi Pharmaceutical Co., Ltd. Hydrazide derivatives
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
PL357284A1 (en) * 2000-03-15 2004-07-26 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
WO2001074817A1 (fr) * 2000-03-30 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Derives d'hydrazide
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
CN100446767C (zh) * 2001-01-31 2008-12-31 H.隆德贝克有限公司 Gal3受体拮抗剂在制备治疗抑郁和/或焦虑药物中的应用及在这种方法中有用的化合物
MXPA04002602A (es) * 2002-02-28 2004-08-11 Japan Tobacco Inc Compuestos de ester y sus usos medicos.
JPWO2003101983A1 (ja) * 2002-05-31 2005-09-29 アステラス製薬株式会社 テトラヒドロピラン誘導体
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
WO2005051382A1 (ja) * 2003-11-28 2005-06-09 Astellas Pharma Inc. 脂質低下作用増強剤
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005097131A2 (en) * 2004-04-09 2005-10-20 Janssen Pharmaceutica N.V. Intermittent dosing regimen for the treatment of overweight with mtp-inhibitors
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
FR2873694B1 (fr) * 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1951224A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EA200801738A1 (ru) * 2006-02-23 2008-12-30 Пфайзер Лимитед Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
EP2040704A2 (en) * 2006-05-18 2009-04-01 Bayer Healthcare Ag Pharmaceutical compositions comprising implitapide and methods of using same
KR20090064478A (ko) 2006-11-13 2009-06-18 화이자 프로덕츠 인크. 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
RU2338745C1 (ru) * 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2008124384A2 (en) * 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
AU2009278838B2 (en) * 2008-08-06 2013-07-25 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
PT2968284T (pt) 2013-03-14 2021-06-28 Osteoqc Inc Derivados alquilamina de harmina para promoção de crescimento ósseo
AU2015311730A1 (en) * 2014-09-05 2017-04-20 Allosteros Therapeutics, Inc Camkii inhibitors and uses thereof
CN108218862B (zh) * 2018-02-07 2020-06-23 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
CN110467560A (zh) * 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR20210075071A (ko) 2018-08-14 2021-06-22 오스테오큐씨 인코포레이티드 피롤로-디피리딘 화합물
WO2020037001A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. FLUORO β-CARBOLINE COMPOUNDS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH501623A (de) * 1967-12-18 1971-01-15 Ruetgerswerke Ag Verfahren zur Herstellung von 2-Chlorpyridin und seinen Derivaten
ATE61047T1 (de) * 1986-01-23 1991-03-15 Merck Frosst Canada Inc Tetrahydrocarbazol-1-alkansaeuren.
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
CA1326030C (en) * 1987-07-21 1994-01-11 John W. Gillard Cyclohept[b]indolealkanoic acids
GB9101375D0 (en) * 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
DE4112533A1 (de) * 1991-04-17 1992-10-22 Bayer Ag Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren
DE4200954A1 (de) 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
DE4308788A1 (de) * 1993-03-18 1994-09-22 Bayer Ag Hetero-tricyclisch-substituierte Phenyl-cyclohexan-carbonsäurederivate
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19613549A1 (de) 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
DE19615119A1 (de) * 1996-04-17 1997-10-23 Bayer Ag Neue Arylessigsäureamide

Also Published As

Publication number Publication date
IL129641A0 (en) 2000-02-29
KR100355986B1 (ko) 2003-01-06
HUT73240A (en) 1996-07-29
MY117282A (en) 2004-06-30
US20020147209A1 (en) 2002-10-10
PH31400A (en) 1998-10-29
PL310756A1 (en) 1996-04-15
US6479503B2 (en) 2002-11-12
IL115493A0 (en) 1996-01-19
SK123995A3 (en) 1996-06-05
UA44700C2 (uk) 2002-03-15
US20030149073A1 (en) 2003-08-07
US5684014A (en) 1997-11-04
IL115493A (en) 1999-10-28
FI20002693A (fi) 2000-12-08
SK284260B6 (sk) 2004-12-01
EP0705831A2 (de) 1996-04-10
PL183154B1 (pl) 2002-05-31
FI108791B (fi) 2002-03-28
NZ280130A (en) 1996-05-28
EE03527B1 (et) 2001-10-15
MA23683A1 (fr) 1996-07-01
HK1005139A1 (en) 1998-12-24
ZA958297B (en) 1996-05-06
SI0705831T1 (en) 2004-02-29
US6265431B1 (en) 2001-07-24
HRP950505B1 (en) 2002-04-30
CN1130631A (zh) 1996-09-11
DE59510839D1 (de) 2004-01-15
HU225052B1 (en) 2006-05-29
IL129641A (en) 2000-08-31
NO953930L (no) 1996-04-09
AU3292095A (en) 1996-04-18
CZ291348B6 (cs) 2003-02-12
HU9502891D0 (en) 1995-11-28
CN1050605C (zh) 2000-03-22
CA2159546A1 (en) 1996-04-05
SV1995000062A (es) 1996-07-10
SG63528A1 (en) 1999-03-30
FI954681A0 (fi) 1995-10-02
HRP950505A2 (en) 1997-08-31
EE9500071A (et) 1996-04-15
JP3901234B2 (ja) 2007-04-04
US6245775B1 (en) 2001-06-12
EP0705831A3 (de) 1997-01-22
KR960014126A (ko) 1996-05-22
CA2159546C (en) 2010-12-14
US6858622B2 (en) 2005-02-22
ATE255580T1 (de) 2003-12-15
NO305365B1 (no) 1999-05-18
ES2211890T3 (es) 2004-07-16
EP0705831B1 (de) 2003-12-03
NO953930D0 (no) 1995-10-03
RU2157803C2 (ru) 2000-10-20
CN1183111C (zh) 2005-01-05
PT705831E (pt) 2004-04-30
TW448175B (en) 2001-08-01
CZ256795A3 (en) 1996-04-17
CN1224715A (zh) 1999-08-04
FI954681A (fi) 1996-04-05
TNSN95098A1 (fr) 1996-02-06
US20020055635A1 (en) 2002-05-09
FI113048B (fi) 2004-02-27
JPH08225526A (ja) 1996-09-03
AU700609B2 (en) 1999-01-07
HN1995009160A (es) 2000-04-24
DZ1934A1 (fr) 2002-02-17
DE4435477A1 (de) 1996-04-11

Similar Documents

Publication Publication Date Title
DK0705831T3 (da) Cycloalkano-indol- og -azaindol-derivater
ATE204269T1 (de) Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
AU2819992A (en) Hiv protease inhibitors useful for the treatment of aids
PL310460A1 (en) Novel derivatives of imidazopyridine, method of obtaining them and drugs containing such derivatives
FR2619111B1 (fr) Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
SI0737678T1 (en) 4-Indolylpiperazinyl derivatives
ATE197794T1 (de) Benzyloxy-substituierte phenylglycinolamide als arzneimittel
AU6193196A (en) Substituted 4H-pyrans
GR3032394T3 (en) Use of 1,2-bridged 1,4-dihydropyridines as selective potassium channel modulators